THE TAPE
DXCM · Medical Instruments · $30.4B

DexCom, Inc.

$81.61▼ −2.06%
Last close
Relative strength
71RS
of 99, against every stock▼ -12 on the month
Cooling off
Strong industry, weak stock
−4.5%
six months against Medical Instruments
52-week range
−11.9%
from the high
$56.72$92.59
Setup
On no screen
No base, flag or squeeze in place tonight. What is and is not there
No report date on the calendar.
Growth FLATProof SHOWN
Quarter to Sep 30, revenue +11% on a year ago
Why it is on no screen

DXCM passes every check below but is not on a screen — the screens also require the base to be the most recent structure, which this one is not.

A base has formed12.0 weeks, from 76.52 to 92.59.
Long enough to count12.0 weeks against 3 needed.
Shallow enough17.4% deep against 35% allowed.
Close to its pivot-11.9% from the pivot; listed down to -20%.
Relative strengthRS 71 against 70 needed.

Measured against the base-and-breakout thresholds. The other screens use their own numbers, so a name can miss here and still be a fair-looking chart.

Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year
Support and resistance
Support below
$79.00
-3.2% · tested 3× · last 3 sessions ago
Resistance above
$82.70
+1.3% · tested 5× · last 23 sessions ago

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

DexCom, Inc. is not on any of the screens right now. Its relative strength rating is 71, and it sits in Medical Instruments.

Against its industry
Strong industry, weak stockBehind its industry over one and six months while the industry is fully aligned and ahead of the S&P 500.
One month against its industry
-8.9%
Three months against its industry
-9.1%
Six months against its industry
-4.5%

Read against an equal-weighted index of Medical Instruments, which is +31.0% against the S&P 500 over six months Fully aligned.

Peers
Same theme
No themes — common and fine.
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 8.7% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$5.1B
+11.2% year on year
Operating margin
24.0%
gross 63.4%
Net margin
19.4%
Free cash flow
$1.1B
3.6% of market cap
Price to sales
5.96×
Price to earnings
30.7×

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Oct 29
Key takeaway
Profitable and cash generating; the question is growth.
Revenue
$1.3B
+2.8% QoQ · +11.2% YoY
Gross margin
64.3%
+0.9 pts QoQ
Net income
$275.1M
Positive
Free cash flow
$272.7M
Cash generating

What the numbers say

  • Revenue +11.2% year over year, +2.8% on the quarter
  • Gross margin 64.3%, +0.9 points on the quarter
  • Good: Profitable: net income $275M, operating margin 24.3%
  • Good: Cash generating: operating cash flow $326M, free cash flow $273M
  • Good: Share count -5.9% in a year: buying back
  • Good: Net cash $961M · cash $961M
Revenue by quarter
Free cash flow
Net income
shares -5.9% in a year · net cash $961.4M
Final read
Growth: FLAT · Economic proof: SHOWN
Key question: Can the cash generation hold as growth slows?
The next test is whether the quarter repeats.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

Held by 1 of 46 tracked funds at the end of Q3 2026.

Last quarter: 1 trimmed.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
GappedTape · 2026-11-07
-6.0%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-11-05
+6.6%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Closed below its 20- and 50-day on heavy volumeTape · 2026-10-31
below 20d & 50d on 1.9x volume at 82.29
No measurable effect: stocks behave like random ones over the next three sessions (1,780 cases over 60 nights).
Reported resultsFiling · 2026-10-30
2.02
No measurable effect: stocks behave like random ones over the next three sessions (2,340 cases over 54 nights).
GappedTape · 2026-10-22
-6.4%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Earnings date movedEvent · 2026-10-21
2026-10-29 -> 2026-10-22
No measurable effect: stocks behave like random ones over the next three sessions (2,989 cases over 51 nights).
Earnings comingEvent · 2026-10-21
reports 2026-10-22
No measurable effect: stocks behave like random ones over the next three sessions (2,970 cases over 40 nights).
Earnings date movedEvent · 2026-10-20
2026-10-22 -> 2026-10-29
No measurable effect: stocks behave like random ones over the next three sessions (2,989 cases over 51 nights).

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Insiders
Bought on the open market
0
Sold on the open market
24
$12,073,902 total

Sold: Stern Sadie, Brown Michael Jon, AUGUSTINOS NICHOLAS, Sylvain Jereme M, SAYER KEVIN R, Heller Bridgette P, FOLETTA MARK G, Coleman Jon.

Not counted above: 22 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-10-30 Ashley Euan A. · Directorgift2,389
2026-10-27 Stern Sadie · EVP Chief People & Culture Offsell2,565$201,660
2026-10-15 Brown Michael Jon · EVP Chief Legal Compliance Offsell1,700$145,316
2026-09-28 Stern Sadie · EVP Chief People & Culture Offsell2,565$220,975
2026-09-15 AUGUSTINOS NICHOLAS · Directorsell6,539$549,538
2026-09-15 Brown Michael Jon · EVP Chief Legal Compliance Offsell1,700$142,868
2026-09-14 AUGUSTINOS NICHOLAS · Directorsell1,550$130,231
2026-09-10 Sylvain Jereme M · EVP, Chief Financal Officersell3,638$302,936

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

What analysts expect
Strong buy4
Buy22
Hold3
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray

No completed base to compare this one with yet.

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
DexCom, Inc. (DXCM) — The Tape